EnVVeno Medical Appoints Jennifer Bright as CFO

enVVeno Medical Corporation, a leader in deep venous disease treatment, has announced Jennifer Bright as its new Chief Financial Officer, effective May 19, 2025. Bright brings over 25 years of financial leadership from companies such as Biolase and Spectrum Pharmaceuticals. Her role will be vital as enVVeno transitions from a development-stage company to a commercial entity. CEO Robert Berman highlights her crucial role in financial strategy and operations, supporting the commercialization of VenoValve, and strengthening investor relations.

Bright, a Certified Public Accountant with a degree from the University of Washington, succeeds Craig Glynn. The company focuses on developing VenoValve® and enVVe® for chronic venous insufficiency (CVI), anticipating FDA decisions for these devices in 2025. Bright's experience is expected to be an asset as enVVeno enters this phase.